Related Experiment Video
Updated: Oct 1, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells
Yuxi Ai1,2, Dongming Liang2, Jeremy E Wilusz1,2,3
1Biochemistry and Molecular Biophysics Graduate Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Abstract:
CRISPR/Cas13 effectors have garnered increasing attention as easily customizable tools for detecting and depleting RNAs of interest. Near perfect complementarity between a target RNA and the Cas13-associated guide RNA is required for activation of Cas13 ribonuclease activity. Nonetheless, the specificity of Cas13 effectors in eukaryotic cells has been debated as the Cas13 nuclease domains can be exposed on the enzyme surface, providing the potential for promiscuous cleavage of nearby RNAs (so-called collateral damage). Here, using co-transfection assays in Drosophila and human cells, we found that the off-target effects of RxCas13d, a commonly used Cas13 effector, can be as strong as the level of on-target RNA knockdown. The extent of off-target effects is positively correlated with target RNA expression levels, and collateral damage can be observed even after reducing RxCas13d/guide RNA levels. The PspCas13b effector showed improved specificity and, unlike RxCas13d, can be used to deplete a Drosophila circular RNA without affecting the expression of the associated linear RNA. PspCas13b nonetheless still can have off-target effects and we notably found that the extent of off-target effects for Cas13 effectors differs depending on the cell type and target RNA examined. In total, these results highlight the need for caution when designing and interpreting Cas13-based knockdown experiments.
Insights
CRISPR-Cas13 RNA knockdown tools can cause significant off-target effects, similar to on-target knockdown levels. Specificity varies by Cas13 type, cell, and target RNA, necessitating careful experimental design.
Area of Science:
- Molecular Biology
- Gene Regulation
- RNA Therapeutics
Background:
- CRISPR/Cas13 systems are versatile RNA-targeting tools.
- Concerns exist regarding Cas13's specificity and potential for off-target RNA cleavage (collateral damage).
Purpose of the Study:
- To investigate the specificity and off-target effects of CRISPR-Cas13 effectors in eukaryotic cells.
- To compare the performance of RxCas13d and PspCas13b in RNA depletion experiments.
Main Methods:
- Co-transfection assays were performed in Drosophila and human cells.
- Expression levels of on-target and off-target RNAs were quantified.
- Different Cas13 effectors (RxCas13d, PspCas13b) and target RNAs were examined.
Main Results:
- RxCas13d exhibited off-target effects comparable to on-target knockdown, correlated with target RNA levels.
- PspCas13b demonstrated improved specificity, enabling selective depletion of a circular RNA without affecting its linear counterpart.
- Off-target effects varied significantly based on cell type and target RNA examined.
Conclusions:
- Cas13-based RNA knockdown requires careful consideration of potential off-target effects.
- The choice of Cas13 effector, target RNA, and cell type influences experimental specificity.
- Caution is advised when designing and interpreting results from Cas13-mediated RNA depletion studies.
More Related Videos
11:37Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
Published on: February 26, 2019
11:35Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells
Published on: June 16, 2017
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
CRISPR
Homologous Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...